| News

BaselArea.swiss welcomes Biopharmaceutical Company Ultragenyx

06.07.2016

BaselArea.swiss Economic Promotion is pleased to announce that Ultragenyx, a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases based in the San Francisco Bay Area, California, is opening their European headquarters in the city of Basel, Switzerland. Stefano Portolano, M.D., has been appointed Senior Vice President and head of Ultragenyx Europe. In this role, Dr. Portolano will be responsible for building and leading the Ultragenyx commercialization efforts across Europe and developing the company's European organization.

DNA (Img: vitstudio/shutterstock)

«Ultragenyx selected Basel as our European headquarters because of the area’s thriving life sciences community, accessibility to the rest of Europe, business-friendly environment and strong international talent pool,» said Dr. Portolano. «On behalf of Ultragenyx, I would like to thank the team at BaselArea.swiss for their partnership throughout this process, as they have been invaluable as we look to establish our European presence and help bring promising therapies to patients throughout the region. We are focusing on key hires to establish necessary capabilities so that we are ready to launch if we receive approval, and we are confident we will be able to find and attract key talents in Basel».

Dr. Portolano brings over 20 years of experience in the biopharmaceutical industry, in medical, commercial and general management roles in both Europe and the United States. He has worked both on pre-launch and launches of products for rare diseases, both at Genzyme and Celgene. Before joining Ultragenyx, he spent ten years at Celgene Corporation in increasing leadership roles, most recently as Vice President of Strategy & Commercial Operations, EMEA. Prior to Celgene, he worked at Genzyme for eight years. Dr. Portolano received his M.D. degree from Federico II University in Napoli, Italy. He completed his postdoctoral fellowship and served as Adjunct Assistant Professor of Medicine at the University of California at San Francisco.

About Ultragenyx
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

The company’s website for more information on Ultragenyx

About BaselArea.swiss
BaselArea.swiss is responsible for the international promotion of the economic region of Basel, Switzerland. In a joint effort, the economic promotion agencies of the Swiss cantons of Basel-Stadt, Basel-Landschaft, and the Jura support expansion and relocation projects of foreign companies, and offer consulting services to entrepreneurs and startups. The identification and procurement of suitable real estate and properties for international and national companies is an important service of BaselArea. BaselArea’s consulting services for interested parties are provided free of charge.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

BLKB supporting startups in Basel region
Basel Area Business & Innovation, Innovation

BLKB supporting startups in Basel region

Basellandschaftliche Kantonalbank (BLKB) has founded the inQbator startup accelerator. Together with its partners Hemex and Launchpad, the bank will be...

Read More
BioVersys receives funding in the fight against tuberculosis
Basel Area Business & Innovation, Invest

BioVersys receives funding in the fight against tuberculosis

The Basel-based pharma company BioVersys has received 2.7 million euros in funding alongside two partners. This financing serves to help...

Read More
Biosynex takes up residence in Delémont
Basel Area Business & Innovation, Invest

Biosynex takes up residence in Delémont

The French company Biosynex develops analytical, diagnostic and prophylactic medical devices. Its portfolio includes a test for COVID-19. It has...

Read More
Novartis Campus opening further
Basel Area Business & Innovation, Switzerland Innovation Park

Novartis Campus opening further

Novartis' 25-year anniversary also marks the next step in the ongoing opening of the campus. The Switzerland Innovation Park Basel...

Read More
docdok.health increases safety of coronavirus vaccinations
Basel Area Business & Innovation, Innovation

docdok.health increases safety of coronavirus vaccinations

The Basel-based start-up docdok.health has developed an app that aims to increase the safety and efficacy of COVID-19 vaccinations. The...

Read More
Hemex attracts Swiss investors
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Hemex attracts Swiss investors

A group of experienced Swiss entrepreneurs and private investors have participated in a significantly oversubscribed financing round for Hemex. The...

Read More
Rhizen drug secures approval in the USA
Basel Area Business & Innovation, Innovation, Invest

Rhizen drug secures approval in the USA

The United States Food and Drug Administration has granted accelerated approval for the drug Umbralisib. Basel biotech Rhizen has discovered...

Read More
Novaremed secures US$50 million
Basel Area Business & Innovation, Innovation, Invest

Novaremed secures US$50 million

Basel biotech Novaremed is receiving US$50 million through an agreement with an investment group. Novaremed will use this financing to...

Read More
Axtria driving growth from Basel
Basel Area Business & Innovation, Innovation, Invest

Axtria driving growth from Basel

The US firm Axtria has established a new office in Basel. The company offers services for the life sciences industry...

Read More
Technologiepark Basel celebrates its role as a driver of innovation
Basel Area Business & Innovation, Innovation, Invest

Technologiepark Basel celebrates its role as a driver of innovation

The Technologiepark Basel will be ten years old in 2021. Over the past decade, it has supported many startups and...

Read More
1 2 3 24

Do you have a question? We'd like to hear from you.